entrance_takeda_i020_v1

Takeda begins world’s first norovirus vaccine field trial

pharmafile | June 22, 2016 | News story | Research and Development Takeda, Vaccine, norovirus 

Takeda Pharmaceuticals (TSE: 4502) has announced that the first patient has received a dosage of their norovirus vaccine candidate, TAK-214, in the world’s first norovirus vaccine field trial.

Norovirus is recognised as the leading cause of acute gastroenteritis across the age spectrum. It is estimated that the infection causes nearly 700 million cases of illness, with more than 200,000 deaths per year attributable to norovirus.

The Phase IIb will evaluate the efficacy of intramuscular administration of the vaccine candidate against moderate or severe acute gastroenteritis due to norovirus. TAK-214 uses virus-like particle (VLP) antigens, which are proteins that precisely mimic the outer surface of norovirus. In this way, it acts in similar way to other vaccines, such as human papillomavirus (HPV) vaccine Gardasil.

Advertisement

In earlier studies, the vaccine was shown to be generally well-tolerated and was associated with a reduction in disease symptoms and severity in a human challenge study.

Robert Goodwin, global norovirus program head for Takeda, says: “Together with our collaborators, Takeda has dedicated a substantial scientific effort to understand the best ways to prevent norovirus illness through vaccination. This trial moves us one step closer to putting an important tool for prevention in the hands of individuals, families and public health systems around the globe.”

Sean Murray

Related Content

drug-trials

BioNet receives positive EMA opinion on new pertussis vaccine

BioNet has received a positive opinion from the Committee for Medicinal Products for Human Use …

Von Willebrand disease – increasing awareness and access to vital care

Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …

Recipharm offers manufacturing support to vaccine trial from ImmBIO and iiCON

Recipharm, a contract development and manufacturing organisation (CDMO), has successfully manufactured PnuBioVax, a new protein-based …

The Gateway to Local Adoption Series

Latest content